Employer profile
AIOS
6 open roles indexed with location, benefit, and apply-link signals where available.
Open roles
Showing the most recent indexed roles for this employer.
-
UK Head of Clinical Product— Hybrid, £85k-£150k/yr inc equity
UK | Hybrid | Remote
hybrid Salary not disclosedUK Head of Clinical Product— Hybrid, £85k-£150k/yr inc equity UK | Hybrid | Remote ABOUT AIOS Our overarching mission is to build the AI operating system for consumer healthcare - delivering end-to-end care with near-zero marginal human time. We believe the future of healthcare is automated, intelligent, radically lower cost, and built around the consumer. We believe biology is entering a golden age. We believe profitable, focused companies beat bloated ones. We're determined to get the humans out of healthcare - replacing slow, expensive, legacy workflows with software-driven care delivered at scale. We've started by building this infrastructure to power our own brands - including Bolt Pharmacy and Fella Health, among others. Today, that infrastructure is helping patients access life-changing treatment for excess bodyweight. Over time, we'll extend it across many of the categories that will define the next era of healthcare. Our infrastructure will have served 100 million patients worldwide by 2035. We'll then use that infrastructure to deliver next-generation healthcare products at massive scale. In doing so, we aim to build the world's first trillion-dollar healthcare company. HOW FAR ALONG ARE WE? We've grown 40x over the past 12 months, now serving 100,000+ patients and surpassing $200M in annual revenue, all while staying cashflow positive. We're a young startup and we're just getting started. This is still Day 1 and all our work is ahead of us. We're backed by top healthcare & consumer investors: - Y Combinator - Global Founders Capital - backed Facebook, Slack, LinkedIn, Revolut,
-
UK Talent Lead at Bolt Pharmacy — On-site, £75k-£100k/yr inc equity
Blackburn, Lancashire | OnSite
onsite $75K-$100KUK Talent Lead at Bolt Pharmacy — On-site, £75k-£100k/yr inc equity Blackburn, Lancashire | OnSite ABOUT AIOS AIOS is building the first vertically integrated AI doctor in Europe. We're >$250M ARR, serving >100k/mo patients, growing >10x YoY. We're Europe's fastest growing healthcare company. We're profitable. As our wedge into the European healthcare system we're using GLP-1s, the fastest growing consumer product in history. We're the only AI-native GLP-1 provider in Europe. Our master plan: - Step 1 → $1Bn/yr: Over the last 12 months we've grown 40x to >100k UK GLP-1 patients. In 2026, we'll hit $1Bn/yr and become #1 GLP-1 provider in UK. - Step 2 → $10Bn/yr: Blitzscale Europe. Become Europe's largest GLP-1 provider by acquiring, retooling, then rapidly scaling regulated infrastructure across the top 10 EU markets, just as we did in the UK. - Step 3 → $100Bn/yr: Use our scale to vertically integrate across agentic patient care, autonomous prescribing, robotic dispensing, and dark factory manufacturing of medication. We'll be the first and only vertically integrated AI doctor in Europe. TLDR = 2026-2030 is the blitzscale landgrab until the semaglutide patent cliff, then we vertically integrate and own the whole value chain. The only way to keep up with this scale is to replace all marginal human time with AI. Our infrastructure will have served 100 million patients worldwide by 2035. We'll then use that infrastructure to deliver next-generation healthcare products at mass scale for low cost so every human can live at least 100 healthy
-
Head of Talent at Aios Medical — Remote, $125k-250k/yr inc equity
Remote (US or European timezones) | Remote | Netherlands | Israel | Berlin | Singapore | UK | Canada | France | US | Sweden
remote $125K-$250KHead of Talent at Aios Medical — Remote, $125k-250k/yr inc equity Remote (US or European timezones) | Remote | Netherlands | Israel | Berlin | Singapore | UK | Canada | France | US | Sweden ABOUT AIOS MEDICAL Our overarching mission is to build the AI operating system for consumer healthcare - delivering end-to-end care with near-zero marginal human time. We are not an average healthcare company. We believe the future of healthcare is automated, intelligent, radically lower cost, and built around the consumer. We believe biology is entering a golden age. We believe profitable, focused companies beat bloated ones. We're determined to get the humans out of healthcare - replacing slow, expensive, legacy workflows with software-driven care delivered at scale. We've started by building this infrastructure to power our own brands - including Bolt Pharmacy and Fella Health, among others. Today, that infrastructure is helping patients access life-changing treatment for excess bodyweight. Over time, we'll extend it across many of the categories that will define the next era of healthcare. Our infrastructure will have served 100 million patients worldwide by 2035. We'll then use that infrastructure to deliver next-generation healthcare products at massive scale. In doing so, we aim to build the world's first trillion-dollar healthcare company. HOW FAR ALONG ARE WE? We've grown 40x over the past 12 months, now serving 100,000+ patients and surpassing $200M in annual revenue, all while staying cashflow positive. We're a young startup and we're just getting started. This is still Day
-
Head of Viral Social (UGC & Clippers) at AIOS — Remote, $200k-$400k/yr + 0.15%-0.50%
Remote (US or European timezones) | Remote
remote $200K-$400KHead of Viral Social (UGC & Clippers) at AIOS — Remote, $200k-$400k/yr + 0.15%-0.50% Remote (US or European timezones) | Remote ABOUT AIOS AIOS is building the first vertically integrated AI doctor in Europe. We're >$250M ARR, serving >100k/mo patients, growing >10x YoY. We're Europe's fastest growing healthcare company. We're profitable. As our wedge into the European healthcare system we're using GLP-1s, the fastest growing consumer product in history. We're the only AI-native GLP-1 provider in Europe. Our master plan: - Step 1 → $1Bn/yr: Over the last 12 months we've grown 40x to >100k UK GLP-1 patients. In 2026, we'll hit $1Bn/yr and become #1 GLP-1 provider in UK. - Step 2 → $10Bn/yr: Blitzscale Europe. Become Europe's largest GLP-1 provider by acquiring, retooling, then rapidly scaling regulated infrastructure across the top 10 EU markets, just as we did in the UK. - Step 3 → $100Bn/yr: Use our scale to vertically integrate across agentic patient care, autonomous prescribing, robotic dispensing, and dark factory manufacturing of medication. We'll be the first and only vertically integrated AI doctor in Europe. TLDR = 2026-2030 is the blitzscale landgrab until the semaglutide patent cliff, then we vertically integrate and own the whole value chain. The only way to keep up with this scale is to replace all marginal human time with AI. Our infrastructure will have served 100 million patients worldwide by 2035. We'll then use that infrastructure to deliver next-generation healthcare products at mass scale for low cost so every human
-
Senior Media Buyer at AIOS — Remote, $150k–$250k/yr inc equity
Remote (US or European timezones) | Remote | US | UK | Canada | France | Berlin | Netherlands | Sweden | Brazil | Argentina | Singapore | India
remote $150K-$250KSenior Media Buyer at AIOS — Remote, $150k–$250k/yr inc equity Remote (US or European timezones) | Remote | US | UK | Canada | France | Berlin | Netherlands | Sweden | Brazil | Argentina | Singapore | India ABOUT AIOS AIOS is building the first vertically integrated AI doctor in Europe. We're >$250M ARR, serving >100k/mo patients, growing >10x YoY. We're Europe's fastest growing healthcare company. We're profitable. As our wedge into the European healthcare system we're using GLP-1s, the fastest growing consumer product in history. We're the only AI-native GLP-1 provider in Europe. Our master plan: - Step 1 → $1Bn/yr: Over the last 12 months we've grown 40x to >100k UK GLP-1 patients. In 2026, we'll hit $1Bn/yr and become #1 GLP-1 provider in UK. - Step 2 → $10Bn/yr: Blitzscale Europe. Become Europe's largest GLP-1 provider by acquiring, retooling, then rapidly scaling regulated infrastructure across the top 10 EU markets, just as we did in the UK. - Step 3 → $100Bn/yr: Use our scale to vertically integrate across agentic patient care, autonomous prescribing, robotic dispensing, and dark factory manufacturing of medication. We'll be the first and only vertically integrated AI doctor in Europe. TLDR = 2026-2030 is the blitzscale landgrab until the semaglutide patent cliff, then we vertically integrate and own the whole value chain. The only way to keep up with this scale is to replace all marginal human time with AI. Our infrastructure will have served 100 million patients worldwide by 2035. We'll
-
Head of Product Growth (Referrals & Viral Loops) at AIOS — Remote, $200k-$400k/yr + 0.15%-0.50%
Remote (US or European timezones) | Remote | UK | India | Berlin | Israel | Canada | France | Netherlands | Singapore | Sweden | US
remote $200K-$400KHead of Product Growth (Referrals & Viral Loops) at AIOS — Remote, $200k-$400k/yr + 0.15%-0.50% Remote (US or European timezones) | Remote | UK | India | Berlin | Israel | Canada | France | Netherlands | Singapore | Sweden | US ABOUT AIOS AIOS is building the first vertically integrated AI doctor in Europe. We're at >$250M ARR, serving >100k/mo patients, growing >10x YoY. We're Europe's fastest growing healthcare company. We're profitable. As our wedge into the European healthcare system we're using GLP-1s, the fastest growing consumer product in history. We're the only AI-native GLP-1 provider in Europe. Our master plan: - Step 1 → $1Bn/yr: Over the last 12 months we've grown 40x to >100k UK GLP-1 patients. In 2026, we'll hit $1Bn/yr and become #1 GLP-1 provider in UK. - Step 2 → $10Bn/yr: Blitzscale Europe. Become Europe's largest GLP-1 provider by acquiring, retooling, then rapidly scaling regulated infrastructure across the top 10 EU markets, just as we did in the UK. - Step 3 → $100Bn/yr: Use our scale to vertically integrate across agentic patient care, autonomous prescribing, robotic dispensing, and dark factory manufacturing of medication. We'll be the first and only vertically integrated AI doctor in Europe. TLDR = 2026-2030 is the blitzscale landgrab until the semaglutide patent cliff, then we vertically integrate and own the whole value chain. The only way to keep up with this scale is to replace all marginal human time with AI. Our infrastructure will have served 100 million patients